Recombinant Human EGFR (ErbB1)

Epidermal growth factor receptor (EGFR, also known as ErbB1 or HER-1), along with receptors ErbB2, ErbB3, and ErbB4, belongs to the receptor tyrosine kinase superfamily and is a transmembrane glycoprotein that activates various signaling pathways fundamental to cellular proliferation, differentiation, and survival^{1, 2}. EGFR consists of an extracellular ligand binding domain, a single transmembrane domain, and an intracellular carboxyl-terminal domain with intrinsic tyrosine activity that, following ligand binding, is responsible for the phosphorylation of signaling molecules and serves as a docking site for intracellular adaptor proteins^{1, 2}. Seven ligands are known to activate EGFR: epidermal growth factor (EGF), transforming growth factor-⍺, heparin-binding EGF, β-cellulin, amphiregulin, epiregulin, and epigen.

EGFR plays important roles during embryogenesis and organogenesis and in the growth, differentiation, maintenance, and repair of adult tissues, including the nervous system². Additionally, EGFR plays a role in skin homeostasis², angiogenesis in wound healing², kidney physiology², and autophagy³. Dysregulation and somatic mutation of EGFR are associated with disease and cancer. Changes to EGFR expression and/or signaling pathways that impact EGFR function are associated with Parkinson’s disease², Alzheimer’s disease^{1, 2}, and amyotrophic lateral sclerosis². In several human cancers (lung, glioblastoma, brain, breast, colorectal, ovarian), EGFR signaling is altered due to EGFR gene amplification and/or protein overexpression, mutations, or in-frame deletions³. Inappropriate activation of EGFR in cancer can also result from abnormal receptor endocytosis and trafficking. EGFR is the target of multiple cancer therapies, including monoclonal humanized antibodies and selective small molecule inhibitors.

Additionally, EGFR is a host factor that facilitates viral entry for hepatitis B⁴, hepatitis C⁵, and gastroenteritis⁶. EGFR also plays a role in SARS-CoV-2 infection and is a possible target of antiviral therapy^{7, 8, 9}.

Human

EGF binding functional assay

leekkvcqgtsnkltqlgtfedhflslqrmfnncevvlgnleityvqrnydlsflktiqevagyvlialntveriplenlqiirgnmyyensyalavlsnydanktglkelpmrnlqeilhgavrfsnnpalcnvesiqwrdivssdflsnmsmdfqnhlgscqkcdpscpngscwgageencqkltkiicaqqcsgrcrgkspsdcchnqcaagctgpresdclvcrkfrdeatckdtcpplmlynpttyqmdvnpegkysfgatcvkkcprnyvvtdhgscvracgadsyemeedgvrkckkcegpcrkvcngigigefkdslsinatnikhfknctsisgdlhilpvafrgdsfthtppldpqeldilktvkeitgflliqawpenrtdlhafenleiirgrtkqhgqfslavvslnitslglrslkeisdgdviisgnknlcyantinwkklfgtsgqktkiisnrgensckatgqvchalcspegcwgpeprdcvscrnvsrgrecvdkckllegeprefvenseciqchpeclpqamnitctgrgpdnciqcahyidgphcvktcpagvmgenntlvwkyadaghvchlchpnctygctgpglegcptngpkips

Lyophilized

100 kDa

69 kDa

69 kDa

This recombinant protein was lyophilized from 0.01M Phosphate Buffered Saline (150mM NaCl) (PBS) pH 7.4, with 5% Trehalose and 1mM TCEP.

Reconstitute at 0.1-1 mg/ml using filtered deionized water. Gently mix by vortexing and/or inversion until fully dissolved. Centrifuge if necessary.

This lyophilized protein is stable for twelve months when stored at -20°C to -70°C. After aseptic reconstitution, this protein may be stored for one month at 2°C to 8°C or for 3 months at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Next Day Ambient

Receptor

Human

Research Use Only

P00533

ELISA
WB
FA

1. Jayaswamy PK, Vijaykrishnaraj M, Patil P, et al. Ageing Res Rev. 83:101791. 2023.
2. Romano R, Bucci C. Cells. 9(8):1887. 2020.
3. Sigismund S, Avanzato D, Lanzetti L. Mol Oncol. 12(1):3-20. 2018.
4. Iwamoto M, Saso W, Sugiyama R, et al. Proc Natl Acad Sci U S A. 116(17):8487-8492. 2019.
5. Lupberger J, Zeisel MB, Xiao F, et al. Nat Med. 17(5):589-595. 2011.
6. Hu W, Zhang S, Shen Y, et al. Virology. 521:33-43. 2018.
7. Klann K, Bojkova D, Tascher G, et al. Mol Cell. 80(1):164-174.e4. 2020.
8. Xu G, Li Y, Zhang S, et al. Cell Res. 31(12):1230-1243. 2021.
9. Wang S, Qiu Z, Hou Y, et al. Cell Res. 31(2):126-140. 2021.
10. van Alderwerelt van Rosenburgh IK, Lu DM, Grant MJ, et al. Nat Commun. 13(1):6791. 2022.